FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 304:76-79 January 8, 1981 Number 2 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

To compare the inhibitory effects of aspirin on prostaglandin synthesized by vessel walls and platelets, we obtained vein segments from five subjects before they were given 150 or 300 mg of aspirin and at various intervals afterward. We then measured prostacyclin (PGI2) synthesis with a radioimmunoassay for its stable metabolite, 6-keto-prostaglandin F1 alpha. Platelet production of thromboxane A2 was measured with a radioimmunoassay for its stable metabolite, thromboxane B2. Two hours after aspirin had been given, 81 to 100 per cent inhibition of PGI2 synthesis was demonstrated; 86 per cent inhibition was still evident in one subject tested eight hours after administration. Simultaneously, platelet production of thromboxane B2 was completely inhibited for more than 24 hours. We conclude that there is little difference between the initial inhibitory response of platelet cyclooxygenase and that of vessel-wall cyclooxygenase to these doses of aspirin. Our results also indicate that in male subjects the prolonged template bleeding time after aspirin is not the consequence of selective inhibition of platelet production of thromboxane.

This article has been cited by other articles:

• Geisler, T, Kapp, M, Gohring-Frischholz, K, Daub, K, Dosch, C, Bigalke, B, Langer, H, Herdeg, C, Gawaz, M (2008). Residual platelet activity is increased in clopidogrel- and ASA-treated patients with coronary stenting for acute coronary syndromes compared with stable coronary artery disease. Heart 94: 743-747 [Abstract] [Full Text]  
• Hennekens, C. H., Borzak, S. (2008). Cyclooxygenase-2 Inhibitors and Most Traditional Nonsteroidal Anti-inflammatory Drugs Cause Similar Moderately Increased Risks of Cardiovascular Disease. J CARDIOVASC PHARMACOL THER 13: 41-50 [Abstract]  
• Patrono, C., Coller, B., FitzGerald, G. A., Hirsh, J., Roth, G. (2004). Platelet-Active Drugs: The Relationships Among Dose, Effectiveness, and Side Effects: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 234S-264S [Abstract] [Full Text]  
• Patrono, C., Coller, B., Dalen, J. E., FitzGerald, G. A., Fuster, V., Gent, M., Hirsh, J., Roth, G. (2001). Platelet-Active Drugs : The Relationships Among Dose, Effectiveness, and Side Effects. Chest 119: 39S-63S [Full Text]  
• Bhagat, K., Collier, J., Vallance, P. (1995). Vasodilatation to Arachidonic Acid in Humans : An Insight Into Endogenous Prostanoids and Effects of Aspirin. Circulation 92: 2113-2118 [Abstract] [Full Text]  
• Thomas, G. R., Thibodeaux, H., Errett, C. J., Bednar, M. M., Gross, C. E., Bennett, W. F. (1995). Intravenous Aspirin Causes a Paradoxical Attenuation of Cerebrovascular Thrombolysis. Stroke 26: 1039-1046 [Abstract] [Full Text]  
• Alhaddad, I. A., Tkaczevski, L., Siddiqui, F., Mir, R., Brown, E. J. Jr (1995). Aspirin Enhances the Benefits of Late Reperfusion on Infarct Shape : A Possible Mechanism of the Beneficial Effects of Aspirin on Survival After Acute Myocardial Infarction. Circulation 91: 2819-2823 [Abstract] [Full Text]  
• Numano, F., Maruyama, Y., Koyama, T., Numano, F. (1986). Antiaggregative Aspirin Dosage at the Affected Vessel Wall. ANGIOLOGY 37: 695-701 [Abstract]  
• Bertele, V, Falanga, A, Tomasiak, M, Dejana, E, Cerletti, C, de Gaetano, G (1983). Platelet thromboxane synthetase inhibitors with low doses of aspirin: possible resolution of the "aspirin dilemma". Science 220: 517-519 [Abstract]